Smart scans may boost radiation success in advanced prostate cancer
NCT ID NCT05924672
First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests whether a special scan called PSMA PET can help pick men with castration-resistant prostate cancer that has spread to the bones who will get the most benefit from Ra-223 radiation therapy. Ra-223 is a radioactive drug that targets bone tumors. The trial enrolled 2 men and aims to see if using PSMA PET leads to better PSA response rates compared to historical results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.